GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (OTCPK:AZNCF) » Definitions » Cyclically Adjusted PB Ratio

AstraZeneca (AstraZeneca) Cyclically Adjusted PB Ratio : 9.35 (As of Jun. 06, 2024)


View and export this data going back to 2009. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PB Ratio?

As of today (2024-06-06), AstraZeneca's current share price is $157.95. AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $16.89. AstraZeneca's Cyclically Adjusted PB Ratio for today is 9.35.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PB Ratio or its related term are showing as below:

AZNCF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.78   Med: 5.62   Max: 10.1
Current: 9.5

During the past years, AstraZeneca's highest Cyclically Adjusted PB Ratio was 10.10. The lowest was 3.78. And the median was 5.62.

AZNCF's Cyclically Adjusted PB Ratio is ranked worse than
92.35% of 732 companies
in the Drug Manufacturers industry
Industry Median: 1.885 vs AZNCF: 9.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AstraZeneca's adjusted book value per share data for the three months ended in Mar. 2024 was $24.155. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $16.89 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.33 7.32 8.24 9.33 8.20

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 8.95 8.70 8.20 8.11

Competitive Comparison of AstraZeneca's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.



AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=157.95/16.89
=9.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=24.155/131.6000*131.6000
=24.155

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201406 17.442 99.800 23.000
201409 16.188 100.000 21.303
201412 15.538 99.900 20.468
201503 13.399 99.600 17.704
201506 14.465 100.100 19.017
201509 13.725 100.200 18.026
201512 14.627 100.400 19.172
201603 11.653 100.400 15.274
201606 10.696 101.000 13.937
201609 10.334 101.500 13.399
201612 11.740 102.200 15.117
201703 10.260 102.700 13.147
201706 10.786 103.500 13.714
201709 10.842 104.300 13.680
201712 11.815 105.000 14.808
201803 10.197 105.100 12.768
201806 9.983 105.900 12.406
201809 9.422 106.600 11.632
201812 9.840 107.100 12.091
201903 7.992 107.000 9.829
201906 10.328 107.900 12.597
201909 9.272 108.400 11.256
201912 10.004 108.500 12.134
202003 8.214 108.600 9.954
202006 9.325 108.800 11.279
202009 9.293 109.200 11.199
202012 11.901 109.400 14.316
202103 10.992 109.700 13.186
202106 11.941 111.400 14.106
202109 25.656 112.400 30.039
202112 25.344 114.700 29.078
202203 23.453 116.500 26.493
202206 23.190 120.500 25.326
202209 22.674 122.300 24.398
202212 23.898 125.300 25.100
202303 23.092 126.800 23.966
202306 24.126 129.400 24.536
202309 23.999 130.100 24.276
202312 25.251 130.500 25.464
202403 24.155 131.600 24.155

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (OTCPK:AZNCF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (AstraZeneca) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (AstraZeneca) Headlines

From GuruFocus